This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsukuda, K. Articles by Amin, K. M. Search for Related Content PubMed PubMed Citation Articles by Tsukuda, K. Articles by Amin, K. M.

An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells

Potent Antitumoral Efficacy but No Toxicity to Normal Cell¹

Department of Surgery [K. T., K. M. A.], Division of Pulmonary, Allergy and Critical Care Medicine [R. W., V. P. J.], and Department of Pathology and Laboratory Medicine [K. M-K.], University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104

To improve the transduction and distribution of adenovirus in a tumor mass, we generated an adenovirus to selectively replicate in tumors. We hypothesized that after infection the replicating adenovirus would spread throughout the tumor mass and cause direct oncolysis of tumor cells. E2F transcription factors are critical regulators of cell growth and are often overexpressed in cancer cells because of the frequent aberrations in the pRb/E2F/p16^INK4a pathway. As a result, a majority of tumor cells exist in a high proliferative state. E2F-1 is a transcription factor that activates its own transcription and that of other genes involved in the G₁ to S transition phase of the cell cycle. We constructed an adenovirus (Ad(E2F-1^RC) so that E1A expression and viral replication were under the control of the human E2F-1 promoter element. AdE2F-1^RC virus replicated as efficiently as the wild-type adenovirus and caused extensive cell killing in a panel of tumor cells in vitro. In contrast, nonproliferating normal epithelial, fibroblast, and endothelial cells, which express no E2F-1, were not able to support AdE2F-1^RC replication. In animal studies, different dosing regimens of AdE2F-1^RC administered to flank xenografts of ovarian and lung cancers led to a significant therapeutic advantage often surpassing that seen in animals treated with the wild-type adenovirus. This novel selectively replicating adenovirus offers a promising treatment platform for a variety of cancers of which the hallmark is uncontrolled cell growth.

This article has been cited by other articles:

				O. Nakajima, A. Matsunaga, D. Ichimaru, Y. Urata, T. Fujiwara, and K. Kawakami Telomerase-specific virotherapy in an animal model of human head and neck cancer Mol. Cancer Ther., January 1, 2009; 8(1): 171 - 177. [Abstract] [Full Text] [PDF]

				P. Monfared, A. Winkeler, M. Klein, H. Li, A. Klose, M. Hoesel, Y. Waerzeggers, S. Korsching, and A. H. Jacobs Noninvasive Assessment of E2F-1-Mediated Transcriptional Regulation In vivo Cancer Res., July 15, 2008; 68(14): 5932 - 5940. [Abstract] [Full Text] [PDF]

				J. Leja, H. Dzojic, E. Gustafson, K. Oberg, V. Giandomenico, and M. Essand A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2455 - 2462. [Abstract] [Full Text] [PDF]

				P. S. Reddy, S. Ganesh, and D.-C. Yu Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin. Cancer Res., May 1, 2006; 12(9): 2869 - 2878. [Abstract] [Full Text] [PDF]

				N. Ramesh, Y. Ge, D. L. Ennist, M. Zhu, M. Mina, S. Ganesh, P. S. Reddy, and D.-C. Yu CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor-Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer Clin. Cancer Res., January 1, 2006; 12(1): 305 - 313. [Abstract] [Full Text] [PDF]

				Y. Li, N. Idamakanti, T. Arroyo, S. Thorne, T. Reid, S. Nichols, M. VanRoey, G. Colbern, N. Nguyen, O. Tam, et al. Dual Promoter-Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models Clin. Cancer Res., December 15, 2005; 11(24): 8845 - 8855. [Abstract] [Full Text] [PDF]

				M. Zhu, J. A. Bristol, Y. Xie, M. Mina, H. Ji, S. Forry-Schaudies, and D. L. Ennist Linked Tumor-Selective Virus Replication and Transgene Expression from E3-Containing Oncolytic Adenoviruses J. Virol., May 1, 2005; 79(9): 5455 - 5465. [Abstract] [Full Text] [PDF]

				R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]

				C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo Genetically modified adenoviruses against gliomas: From bench to bedside Neurology, August 10, 2004; 63(3): 418 - 426. [Abstract] [Full Text] [PDF]

				T. Shirakawa, K. Hamada, Z. Zhang, H. Okada, M. Tagawa, S. Kamidono, M. Kawabata, and A. Gotoh A Cox-2 Promoter-Based Replication-Selective Adenoviral Vector to Target the Cox-2-Expressing Human Bladder Cancer Cells Clin. Cancer Res., July 1, 2004; 10(13): 4342 - 4348. [Abstract] [Full Text] [PDF]

				K. Hamada, S. Kohno, M. Iwamoto, H. Yokota, M. Okada, M. Tagawa, S. Hirose, K. Yamasaki, Y. Shirakata, K. Hashimoto, et al. Identification of the Human IAI.3B Promoter Element and Its Use in the Construction of a Replication-selective Adenovirus for Ovarian Cancer Therapy Cancer Res., May 15, 2003; 63(10): 2506 - 2512. [Abstract] [Full Text] [PDF]

				J. Fueyo, R. Alemany, C. Gomez-Manzano, G. N. Fuller, A. Khan, C. A. Conrad, T.-J. Liu, H. Jiang, M. G. Lemoine, K. Suzuki, et al. Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway J Natl Cancer Inst, May 7, 2003; 95(9): 652 - 660. [Abstract] [Full Text] [PDF]

				J. L. Jakubczak, P. Ryan, M. Gorziglia, L. Clarke, L. K. Hawkins, C. Hay, Y. Huang, M. Kaloss, A. Marinov, S. Phipps, et al. An Oncolytic Adenovirus Selective for Retinoblastoma Tumor Suppressor Protein Pathway-defective Tumors: Dependence on E1A, the E2F-1 Promoter, and Viral Replication for Selectivity and Efficacy Cancer Res., April 1, 2003; 63(7): 1490 - 1499. [Abstract] [Full Text] [PDF]

				J. R. Bertino and D. Banerjee Is the Measurement of Thymidylate Synthase to Determine Suitability for Treatment with 5-Fluoropyrimidines Ready for Prime Time? Clin. Cancer Res., April 1, 2003; 9(4): 1235 - 1239. [Full Text] [PDF]